INTRODUCTION
The tumor suppressor p53 is mutated and inactivated in about half of all human cancers examined (1) . The ability to induce cell cycle arrest and programmed cell death (apoptosis) is vital to its role as a tumor suppressor, thereby preventing the propagation of cells that may be undergoing malignant transformation. However, the molecular mechanism by which p53 initiates cell cycle arrest and apoptosis remains unknown. Recently, it has been suggested that the breast cancer tumor suppressor gene product BRCA1 functions as a molecular scaffold, assembling proteins involved in fine-tuning the p53 response (2) .
The p53 protein is almost undetectable in resting cells due to the action of its inhibitor MDM2, also a p53 target gene. This inhibitor stimulates the ubiquitination of p53 and targets it for degradation by the proteasome (3). Thus, p53 directly controls the expression of its own negative regulator, creating a negative feedback loop. p53 protein levels have been shown to rise dramatically in response to diverse cellular stresses including ionizing and UV irradiation, hypoxia, heat shock, viral infection, and treatment with chemotherapeutic agents (reviewed in Ref. 4 ). Activated p53 is stabilized by posttranslational modifications, allowing it to either activate or repress a wide range of different gene targets. These in turn can regulate cell cycle and growth arrest, e.g. target gene p21 Waf1/Cip1 (p21) (5) , or can lead to various other outcomes, including DNA repair and apoptosis (reviewed in Ref. 6 ).
which p53 regulates apoptosis is unclear. Since no single gene has been shown to sufficiently mediate the full apoptotic effect, it is likely that p53 activates a network of apoptotic genes.
To understand the apoptotic pathway(s), it is essential to identify and characterize additional targets.
Using Differential Display (9), we isolated a cDNA fragment that was up-regulated after p53 induction. Sequence results revealed that this transcript was identical to NDRG1
(N-myc Down-Regulated Gene 1) (10, 11) , also known as Drg1, Cap43, RTP/rit42, and Proxy-1 (12) (13) (14) (15) . To date, the exact biological function of NDRG1 remains obscure. Here, we report that NDRG1 is a direct transcriptional target gene of p53. Functional studies using RNA interference and inducible gene expression approaches suggest that NDRG1 is necessary but not sufficient for p53-induced apoptosis. In addition, this study describes a novel biological role of NDRG1 as a mediator of cell death, which is regulated by p53.
EXPERIMENTAL PROCEDURES
Cell Culture and Treatment-Human colorectal adenocarcinoma cell lines HCT116 p53+/+ (expressing endogenous wild-type p53) and HCT116 p53-/-(with a targeted deletion of p53 (16)) were kindly provided by B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA). The human colorectal adenocarcinoma cell line DLD-1 (expressing a mutant, inactive form of p53) was a gift from R. Coffey (Vanderbilt University). HCT116 and DLD-1 cells were treated with 1 µM doxorubicin (dox 1 ) (Sigma-Aldrich) and harvested at the indicated time points. Human colorectal regulated transactivator) and H1299-p53 (expressing inducible wild-type p53 after tetracycline removal) were a gift from C. Prives (Columbia University, New York, NY, USA). The H1299-p53 cells correlate to the "p53-3 clone" of the metastatic lung cancer cell line H1299 with tetracyclineregulated p53 expression described by Chen et al. (18) .
All human colon cancer cells were maintained in McCoy's 5A medium (Invitrogen), whereas the human lung cancer cell lines were maintained in Dulbecco's modified Eagle's medium (Invitrogen). The media were supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillinstreptomycin (Invitrogen). Cells were cultured at 37ºC in 10% CO 2 .
To induce tetracycline-controlled gene expression in "tet-off" cell systems, tetracycline was removed from the culture medium using the following procedure: cells were washed gently three times in the recommended medium either supplemented with tetracycline (no gene induction) or without tetracycline (gene induction). After a 1-hour incubation at 37ºC, all wash steps were repeated, and cell growth was allowed to proceed in the recommended medium.
Fluorescent Differential Display (FDD)-FDD reactions were performed as previously described (19) . Briefly, total RNA from DLD-1-p53 cells with or without tetracycline was extracted using the RNApure Reagent (GenHunter). FDD-PCR reactions were carried out using the RNAspectra Red Kit (GenHunter), according to the manufacturer's recommendations. After cDNAs were generated from the 3' termini of mRNAs, the PCR products were separated by electrophoresis on a 6% denaturing polyacrylamide gel. The gel was scanned with the Hitachi Genetic Systems FMBIO II Fluorescence Imaging System (Hitachi). Bands representing cDNAs of interest were excised from the gel. The cDNAs were eluted and re-amplified to avoid false-positive bands. All re-amplified cDNA fragments were extracted from the agarose gel with the Qiaex II Gel Extraction Kit (Qiagen), cloned into the pCR-TRAP vector (GenHunter), and sequenced (Vanderbilt University, DNA Sequencing Facility).
Northern Blotting-Northern blot analysis was used to confirm the differential gene expression results, as previously described (19) . In brief, total RNA was isolated following the above protocol. agarose top layer. The antibiotics G418 (250 µg/ml) and puromycin (10 µg/ml) were added to both layers. As a control, cells also were grown on soft agar plates containing tetracycline (1 µg/ml) to suppress NDRG1 expression. The plates were incubated at 37ºC for three to four weeks, then the number of colonies >50 µm in diameter were quantitated using the Omnicon Colony Counter (Bausch and Lomb). Assays were performed in triplicate.
Western Blot Analysis-Cells were washed twice with ice-cold PBS. Total cell lysates were prepared in KLB buffer as previously described (21) . Protein concentrations were determined using Bio-Rad Protein Assay Dye Reagent (Bio-Rad). Aliquots (25 to 50 µg) of whole protein lysates were loaded onto SDS-PAGE (7 to 10%) gels. For Western blot analysis, proteins were blotted onto PVDF membranes (Millipore). The membranes were blocked with 5% non-fat milk in Tris-buffered saline and reverse 5'-CTGGGCATTGGGGTTTTTAC-3' (upstream of this potential binding site) was used as a negative control for this assay. Five µl of purified DNA was utilized as a template for the PCR reaction. Precipitated DNA was amplified by standard PCR using Taq polymerase (Qiagen). PCR amplifications were performed as previously described (21) . PCR products were separated on a 1.2% agarose gel and visualized by ethidium bromide staining.
Luciferase Reporter Assay-The sequence of the human NDRG1 promoter region was assembled using public databases. Genomic DNA isolated from human 293T cells was kindly The obtained PCR products were cloned into the SacI and NheI site of the pGL3 basic vector (Promega). All constructs were sequenced to verify the authenticity of the cloned promoter regions (Georg-Speyer-Haus, Frankfurt/Main, Germany, DNA Sequencing Facility). These reporters (0.6 µg)
were co-transfected into 293T cells (on 12-well plates) with either pCEP4-p53 (0.9 µg) or pCEP4 (0.9 µg) and SV40-β-Gal (0.1 µg) using 4 µl of Lipofectamine 2000 (Invitrogen). The β-galactosidase reporter was included as a control for transfection efficiency. After 24 hours, cells were washed with PBS, and 150 µl lysis buffer (50 mM Mes-Tris pH 7.8, 1 mM DTT, 0.1% Triton-X100, 10%
Glycerin, protease inhibitor cocktail (Roche)) was added to each well. Cells were collected by scraping and subjected to one freeze-thaw cycle, followed by centrifugation. Supernatants were assayed for luciferase and β-galactosidase activity. Luciferase activity (10 µl cell extract and 50 µl luciferase buffer (300 µg/ml luciferin, 125 mM 50mM Mes-Tris pH 7.8, 25 mM MgCl 2 , 4 mM ATP)) was quantified by the Luminometer 953 (Berthold, Pforzheim, Germany) and normalized to β-galactosidase activity. For β-galactosidase determination, 5 µl of cell extract was added to 180 µl of working lacZ buffer pH 7.0 (50 mM Na 2 HPO 4 x 7 H 2 O, 21 mM NaH 2 PO 4 x H 2 O, 10 mM KCl, 1 mM MgSO 4 , 0.28% β-mercaptoethanol, 1% SDS). After adding 18.5 µl of CPRG substrate (Roche, 15 mg/ml) to the mixture, reactions were incubated at 37°C until an orange color was produced. At least three independent experiments were performed. Empty pGL3 basic vector served as a negative control. (Fig. 1A) , whose sequences corresponded to NDRG1. The expression of NDRG1 was markedly up-regulated following p53 induction (Fig. 1A) . To confirm the expression of NDRG1 by elevated p53 in these cells, Northern and Western blot analyses were completed (Fig. 1B and C) . As shown in Fig. 1 , NDRG1 was significantly increased 8
hours after tetracycline removal in DLD-1-p53 cells, suggesting that it is an early p53-induced gene. To determine whether NDRG1 can be induced by endogenous p53 through DNA damage, the HCT116 p53+/+ cell line was analyzed. Induction of p53 expression following treatment with the DNA-damaging reagent doxorubicin resulted in elevation of NDRG1 expression (Fig. 1C) . Furthermore, no increase in the basal level of NDRG1 was obtained in either HCT116 p53-/-or DLD-1 cells after doxorubicin treatment (Fig. 1C and data not shown). These results suggest that p53 induction leads to the expression of endogenous NDRG1.
Remarkably, NDRG1 expression was not detected in the inducible p53 human lung cancer cell line H1299 (H1299-p53) (Fig. 1C) . Moreover, no changes in BRCA1 expression levels were obtained after p53 activation in these cells (Fig. 1C) . Previous studies have demonstrated a functional interaction between these proteins, and it has been shown that BRCA1 enhances p53 transcription, whereas activated p53 represses BRCA1 (27, 28), which we have confirmed in the colon cancer cells used in this study (Fig. 1C) . In contrast, other downstream targets, such as p21 and HDM2, were readily induced after p53 induction in H1299-p53 cells (Fig. 1C and data not shown) . In summary, these data indicate that NDRG1 for the putative binding site of the NDRG1 promoter. As shown in Fig. 2B , the ChIP assays demonstrate that p53 binds to this site. As expected, no specific PCR products were amplified using primers binding upstream of this specific site (data not shown). Since p21 is a major downstream target of p53, we used the well-characterized p53 binding site 1 (BS1) of the p21 promoter as a positive control for this assay ( Figs. 2A and B) .
To determine whether the p53 binding site of the NDRG1 gene was primarily responsible for the p53 responsiveness to transcriptional activation, we tested luciferase reporter constructs containing the wild-type (WT), mutant (MUT) or deleted (DEL) forms of the p53 binding site (Fig. 2C ). 293T cells were co-transfected with the different reporter constructs in the absence or presence of p53. As shown in Fig. 2C , an increase in the luciferase activity was observed for the wild-type p53 binding site in the presence of p53. In contrast, when the p53 binding site was either mutated or deleted, p53-mediated transciptional activation was greatly diminished (Fig. 2C) . Taken together, these data provide the evidence that NDRG1 is a direct target gene of p53. To determine if NDRG1 has any effect on cell growth, we performed proliferation assays with or without tetracycline (Fig. 3B ). Our results demonstrate that NDRG1 induction inhibits cell proliferation of the metastatic H1299-NDRG1 lung cancer cells, but has no influence on the non-metastatic DLD-1-NDRG1 colon cancer cells (Fig. 3B) . Furthermore, enhanced NDRG1 expression in both cell lines fails to elicit any characteristic signs of apoptosis (data not shown).
Inducible Expression of NDRG1 Suppresses Cell Growth in Metastatic but not in
To further confirm that NDRG1 plays an inhibitory role in cell proliferation in the metastatic H1299-NDRG1 cells, we performed clonogenic assays (colony formation assays)
to evaluate the ability of these cells to grow in soft agar. As shown in Fig. 3C , induction of NDRG1 in the H1299-NDRG1 cells significantly inhibited the number of colonies formed, consistent with NDRG1's effect on cell proliferation. As expected, no significant differences (Fig. 4A) . A selective knockdown of p53 using the pSUPER-p53 construct led to reduced NDRG1 expression levels in DLD-p53 cells, establishing it as a direct target gene (Fig. 4A) . Additionally, the detection of BRCA1 and the decrease of p21 expression levels, as compared to the control cells, indicated that p53 was successfully knocked-down (Fig. 4A) . To selectively knockdown NDRG1 in DLD-1-p53 cells, we designed two different NDRG1 siRNA constructs targeting the cDNA sequence at positions 398 to 416 and 601 to 619. After transfecting the individual pSUPER-NDRG1
constructs into these cells, we obtained a number of cell clones that showed decreased NDRG1 expression for both siRNA constructs after tetracycline removal ( Fig. 4A and data not shown). Importantly, although siRNA knockdown of NDRG1 did not affect the induction of p53 or certain p53 target genes, such as p21 and HDM2, BRCA1 expression was still observed (Fig. 4A ).
To determine whether NDRG1 contributes to p53-mediated apoptosis, we analyzed (Fig. 4A) . Second, NDRG1 siRNA cells underwent significant G1 arrest upon p53 induction, which was manifested by a marked increase in G1 phase DNA content and by a decrease in the S phase DNA content as compared to p53 siRNA cells (Fig. 4C) . Taken together, results from the siRNA-mediated knockdown studies suggest that NDRG1 is required for p53-mediated apoptosis.
NDRG1 Sensitizes Cells to p53-mediated Apoptosis-Contrary to the colon cancer cells used in this study, the lung cancer cell line H1299-p53 failed to activate NDRG1 expression (Fig. 1C) . This cell line mainly undergoes growth arrest, rather than apoptosis, following p53 expression (18, 31) . Thus, we wanted to determine whether forced expression of NDRG1 in H1299-p53 cells would enhance p53-mediated apoptosis. Constitutive expression of N-terminal FLAG-tagged NDRG1 in H1299-p53 cells was achieved by Page 15 by guest on July 15, 2017
http://www.jbc.org/ Downloaded from transfection using the pCMV-FLAG-NDRG1 vector (Fig. 5A) . Following p53 induction, H1299-p53 cells with ectopic NDRG1 expression exhibited an increase in cell apoptosis, as observed by the elevated number of dead cells (data not shown), cleavage of caspase 3 and PARP (Fig. 5A) , and an increase in the sub-G1 cellular DNA content (Fig. 5B) . In contrast, both mock and vector (pCMV-FLAG) transfected cells showed little p53-regulated apoptosis and only full-length PARP (Fig. 5A and B , and data not shown). These results, together with the findings from our siRNA knockdown studies, indicate that NDRG1 is necessary for p53-dependent caspase activation as well as cell apoptosis.
Intracellular Calcium Release Induces NDRG1 Expression-To examine whether the H1299-p53 cells have completely lost the ability to express endogenous NDRG1 due to chromosomal DNA deletions or mutations, we treated the cells with the calcium ionophore A23187, since intracellular calcium release enhances NDRG1 expression (32) . Applying semi-quantitative RT-PCR, we determined that NDRG1 expression is activated by calcium;
however, in a p53-independent manner (Fig. 6 ). This induction was completely blocked by the calcium chelator BAPTA/AM (Fig. 6) . Similar results were obtained with the DLD-1-p53
and HCT116 p53+/+ cells (data not shown). Other target genes, such as p21, also were elevated by calcium independently of p53, while BRCA1 expression levels were decreased ( Importantly, NDRG1 expression did not occur in the metastatic human colon cancer cell line SW620 (33), suggesting that it plays different roles in metastatic versus non-metastatic cells.
Previous reports (14, 33) , combined with the data from our NDRG1-inducible cell system approaches, support this idea. Forced expression of NDRG1 suppresses cell growth of H1299-NDRG1 metastatic lung cancer cells, but not the DLD-1-NDRG1 non-metastatic colon cancer cells. Additionally, it has been proposed that NDRG1 is functionally linked to NDRG1 is one of four members of a new gene family that share over 65% amino acid identity, but little is known about them (36) . NDRG1 is the most studied gene among this family and encodes a 43 kD protein containing a tandem repeat sequence of ten amino acids on the C-terminus that is likely involved in the binding of heavy metal ions, such as nickel and copper (37) . This gene has been mapped to the human chromosome 8q24.3 (14) and mutations in the gene product are associated with neuronal diseases (38) (39) (40) . Recently, NDRG1 was shown to localize primarily to the cytoplasm (12, 14, 34) , which was confirmed by our studies (data not shown). NDRG1, however, also has been found in the nucleus (14, 34) . So far, no nuclear localization signal (NLS) sequence has been identified for this gene.
Therefore, NDRG1 might interact with other nuclear proteins. Additionally, potential phosphorylation sites have been suggested, which might contribute to its localization to the nucleus (41, 42) . NDRG1 is induced by a variety of stresses, such as homocysteine (43), nickel (13), androgens (44, 45) , calcium (32) , and hypoxia (15, 46) . These indicate that NDRG1 is linked to different biological processes, such as nickel carcinogenesis (13) and cell differentiation (12, (47) (48) (49) (50) (32, 56) . Indeed, an increase in NDRG1 expression was observed when the calcium ionophore A23187 was applied to release intracellular calcium in the H1299-p53 cells, and chelation of intracellular calcium by BAPTA/AM abolished this expression. Therefore, it seems that the induction of NDRG1 expression by hypoxia can be regulated through calcium release. Alternatively, it also has been demonstrated that hypoxia leads to p53 accumulation and stabilization (57) . Thus, our study provides evidence that p53
and/or calcium release may be the link(s) between hypoxia and NDRG1 induction.
During our experiments we observed an inverse correlation between BRCA1 and NDRG1 expression, irrelevant of p53 status. Since no changes in BRCA1 expression levels were detected in the NDRG1-inducible cell lines following NDRG1 induction, we assume that NDRG1 alone is not directly linked to BRCA1 expression (data not shown).
Although Kurdistani et al. (14) previously showed that NDRG1 expression is increased following p53 induction, the relevance of NDRG1 in p53-regulated pathway(s)
remains to be clarified. The data presented here suggest that NDRG1 is necessary but not sufficient for caspase activation and apoptosis initiated by p53 in DLD-1-p53 cells.
Furthermore, H1299-p53 cells, which normally undergo minimal cell death after p53 induction (18, 31) , were sensitized towards caspase activation and apoptosis by forced NDRG1 expression. In conclusion, we have identified NDRG1 as a direct target gene of p53
and have shown that its expression is necessary but not sufficient for the execution of the apoptotic program controlled by the p53 tumor suppressor gene. Our data strongly support the current model for p53-dependent apoptosis, suggesting a more complex mechanism in which NDRG1 has an essential role to play.
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